Abstract: The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.

Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.

Abstract: The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.

Abstract: Provided herein are compounds, compositions containing the compounds, and methods for the treatment of cancer in a cancer patient. In particular, the compounds are made by a process comprising treating a first compound represented by either Formula G? or Formula M?: with a second compound of generalized formula R8R9C(OCH3)2 and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein R1 and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; R7 is an alkyl group, an olefinic group, or an aromatic group; P1 is a hydroxyl protecting group; P5 is H or an acid labile protecting group at the 7-O position; R8 is H, alkyl group, olefinic or aromatic group; and R9 is: H, alkyl group, olefinic or aromatic or is as defined in the specification.

Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.

Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.

Abstract: The present application relates to new taxane analogs, pharmaceutical compositions comprising such analogs and methods of treating cancer comprising such compositions. The compounds according to the present application have the general formula: wherein R1 and R2 are each selected from H, alkyl, alkenyl or aryl; R3 is hydroxyl or OP1; R4 is OH or R7COO; R7 is alkyl, alkenyl or aryl, R8 and R9 are each independently selected from H, alkyl or alkenyl. The compounds of the present application may particularly be 9,10-?,?-OH taxane analogs that are formed by a process starting with a standard taxane as the starting compound.

Abstract: The present invention relates to a method for the treatment of cancer in a cancer patient.

Abstract: The present application relates to new taxane analogs, pharmaceutical compositions comprising such analogs and methods of treating cancer comprising such compositions. The compounds according to the present application have the general formula: wherein R1 and R2 are each selected from H, alkyl, alkenyl or aryl; R3 is hydroxyl or OP1; R4 is OH or R7COO; R7 is alkyl, alkenyl or aryl, R8 and R9 are each independently selected from H, alkyl or alkenyl. The compounds of the present application may particularly be 9,10-?,?-OH taxane analogs that are formed by a process starting with a standard taxane as the starting compound.

Abstract: The present invention relates to a method for the treatment of cancer in a cancer patient.

Abstract: The present invention relates to taxane analogs for the treatment of cancer having the general formula: wherein R1 and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; R3 is hydroxyl or OP1; R4 and R5 are each hydroxyl or R7COO; R6 is hydroxyl, OP2, R7COO, or an ether functionality; R7 is an alkyl group, an olefinic group, or an aromatic group; P1 and P2 are each hydroxyl protecting groups; R8 and R9 are each selected from H, alkyl group, olefinic or aromatic group. The present invention is also directed to production methods and intermediates useful in the formation of these new taxane analogs. The methods may begin with a starting compound, such as paclitaxel or docetaxel, which is converted into a taxane analog through various intermediate compounds.

Abstract: The application provides a process for the preparation of taxane derivatives and intermediates useful in such processes.

Abstract: The present invention is broadly directed to novel compounds useful for the synthesis of biologically active compounds, including taxane derivatives, and convergent processes for the preparation of these taxane derivatives and their intermediates.

Abstract: The present invention relates generally to effective drug-linker constructs suitable for conjugation with ligands. The present invention also discloses methods of conjugating these constructs with peptides to form the compound of formula I. These methods are readily extended to any hydroxyl, amine or sulfur bearing biologically active molecules.

Abstract: The present invention is broadly directed to novel compounds useful for the synthesis of biologically active compounds. More particularly, the present embodiments disclosed herein relate to novel side chains, that when coupled to a taxane, are useful for the synthesis of pharmaceutically useful taxanes. Methods of forming the novel side chains and coupling them to hindered alcohols, namely taxanes resulting in useful esters are also disclosed. Various taxanes compounds are known to exhibit anti-tumor activity.

Abstract: The present application relates to new taxane analogs, pharmaceutical compositions comprising such analogs and methods of treating cancer comprising such compositions. The compounds according to the present application have the general formula: wherein R1 and R2 are each selected from H, alkyl, alkenyl or aryl; R3 is hydroxyl or OP1; R4 is OH or R7COO; R7 is alkyl, alkenyl or aryl, R8 and R9 are each independently selected from H, alkyl or alkenyl. The compounds of the present application may particularly be 9,10-?,?-OH taxane analogs that are formed by a process starting with a standard taxane as the starting compound.

Abstract: The present application relates to new taxane analogs, pharmaceutical compositions comprising such analogs and methods of treating cancer comprising such compositions. The compounds according to the present application have the general formula: wherein R1 and R2 are each selected from H, alkyl, alkenyl or aryl; R3 is hydroxyl or OP1; R4 is OH or R7COO; R7 is alkyl, alkenyl or aryl, R8 and R9 are each independently selected from H, alkyl or alkenyl. The compounds of the present application may particularly be 9,10-?,?-OH taxane analogs that are formed by a process starting with a standard taxane as the starting compound.

Abstract: The present invention is broadly directed to novel compounds useful for the synthesis of biologically active compounds, including taxane derivatives, and convergent processes for the preparation of these taxane derivatives and their intermediates.